- Biotechnology company ValiRx said it had 'endorsed' the UK government's NHS long-term plan to improve the quality of patient care and health outcomes.

The NHS announced the new 10-year plan on Monday, which was partly aimed at detecting diseases such as cancer early.

'ValiRx's stated ambition, for some time, has been the personalisation of novel therapeutics and through genetic mapping, to facilitate the early detection of cancers,' the company said.

'This ambition has long been at the forefront of much of ValiRx's work in the oncology arena and it is excellent news that the government is now actively discussing and championing these therapeutic and diagnostic approaches.'

ValiRX said it was 'among the front runners contributing to this government and NHS-led initiative'.

At 1:45pm: [LON:VAL] ValiRx PLC share price was -0.03p at 0.8p

Story provided by